We are live on ! Find out more
AERI

Aerie Pharmaceuticals
AERI

Delisted

AERI was delisted on the 18th of November, 2022.

Back to rankings

175 hedge funds and large institutions have $2.94B invested in Aerie Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 73 increasing their positions, 55 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more funds holding in top 10

Funds holding in top 10: 7 → 10 (+3)

33% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 55

26% more capital invested

Capital invested by funds: $2.33B → $2.94B (+$615M)

15% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 20

2% more funds holding

Funds holding: 172 → 175 (+3)

40% less call options, than puts

Call options by funds: $20.6M | Put options by funds: $34.6M

Holders
175
Holders Change
+3
Holders Change %
+1.74%
% of All Funds
4.01%
Holding in Top 10
10
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+42.86%
% of All Funds
0.23%
New
23
Increased
73
Reduced
55
Closed
20
Calls
$20.6M
Puts
$34.6M
Net Calls
-$14M
Net Calls Change
-$8.1M

Top Buyers

Rank Fund Capital Flow
1
FCM
Frontier Capital Management
Massachusetts
+$20.4M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$18.4M
3
Bank of America
Bank of America
North Carolina
+$14.6M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$13.9M
5
BlackRock
BlackRock
New York
+$13.8M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$17.9M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$15.2M
3
FCMI
Foresite Capital Management III
California
-$13.6M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$12.1M
5
FCMI
Foresite Capital Management II
California
-$11.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Balyasny Asset Management
26
Balyasny Asset Management
Illinois
$26M +$18.4M +328,442 +578%
FCM
27
Frontier Capital Management
Massachusetts
$24.7M +$20.4M +365,435 New
T. Rowe Price Associates
28
T. Rowe Price Associates
Maryland
$24.3M +$1.05M +18,727 +5%
Neuberger Berman Group
29
Neuberger Berman Group
New York
$23.1M +$1.16M +20,800 +6%
Ameriprise
30
Ameriprise
Minnesota
$21.6M +$2.28M +40,717 +15%
O
31
OppenheimerFunds
New York
$21.6M +$974K +17,415 +6%
Handelsbanken Fonder
32
Handelsbanken Fonder
Sweden
$20.6M +$2.52M +45,000 +17%
Loomis, Sayles & Company
33
Loomis, Sayles & Company
Massachusetts
$20.5M +$2M +35,672 +13%
Norges Bank
34
Norges Bank
Norway
$20.2M – – –
Russell Investments Group
35
Russell Investments Group
United Kingdom
$20.1M +$304K +5,434 +2%
RHJA
36
Rice Hall James & Associates
California
$19.2M +$535K +9,563 +3%
PC
37
PointState Capital
New York
$19M +$13.2M +236,524 +525%
Millennium Management
38
Millennium Management
New York
$17.5M -$7.22M -129,012 -33%
CS
39
Credit Suisse
Switzerland
$16M -$5.21M -93,177 -28%
EP
40
Eversept Partners
New York
$15.3M +$902K +16,124 +8%
SCM
41
Suffolk Capital Management
New York
$14.3M -$152K -2,717 -1%
Deutsche Bank
42
Deutsche Bank
Germany
$13.6M +$7.62M +136,118 +209%
Charles Schwab
43
Charles Schwab
California
$13.5M +$969K +17,314 +9%
FAM
44
Fred Alger Management
New York
$12.4M -$7.92M -141,625 -44%
Point72 Asset Management
45
Point72 Asset Management
Connecticut
$12.3M +$10.2M +182,300 New
Axa
46
Axa
France
$11.7M +$123K +2,203 +1%
SPPAM
47
Summit Partners Public Asset Management
Massachusetts
$11.5M +$2.8M +50,000 +42%
DCM
48
DAFNA Capital Management
California
$8.9M -$56K -1,000 -0.8%
NHAS
49
Novo Holdings A/S
Denmark
$8.54M +$7.07M +126,397 New
CS
50
Candriam SCA
Luxembourg
$8.22M +$2.39M +42,700 +54%
1
2
3 4 5

AERI Hedge Fund Activity: Q2 2018 in Review

175 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q2 2018, worth a combined $2.94B — up 26% from $2.33B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new AERI positions and 20 closed out — a net gain of 3 holders — while 73 added to existing stakes and 55 trimmed.

The largest buyer was Frontier Capital Management, opening a new position worth an estimated $20.4M. The largest seller was Morgan Stanley, cutting an estimated $17.9M.

  • 175 institutional investors held Aerie Pharmaceuticals (AERI) as of Q2 2018, up from 172 in Q1 2018.
  • Funds reported $2.94B of Aerie Pharmaceuticals stock for Q2 2018, up 26% quarter-over-quarter.
  • 23 funds opened new Aerie Pharmaceuticals positions in Q2 2018 and 20 closed out, a net change of +3 holders.
  • The largest Aerie Pharmaceuticals buyer in Q2 2018 was Frontier Capital Management, an estimated $20.4M added.
  • The largest Aerie Pharmaceuticals seller in Q2 2018 was Morgan Stanley, an estimated $17.9M sold.

Based on aggregated 13F filings for Q2 2018.